- Home
- TCPC vs FBIO Comparison
TCPC vs FBIO Comparison
Compare TCPC & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCPC
- FBIO
- Stock Information
- Founded
- TCPC 2006
- FBIO 2006
- Country
- TCPC United States
- FBIO United States
- Employees
- TCPC N/A
- FBIO N/A
- Industry
- TCPC Finance/Investors Services
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- TCPC Finance
- FBIO Health Care
- Exchange
- TCPC Nasdaq
- FBIO Nasdaq
- Market Cap
- TCPC N/A
- FBIO 44.0M
- IPO Year
- TCPC 2012
- FBIO N/A
- Fundamental
- Price
- TCPC $6.79
- FBIO $1.53
- Analyst Decision
- TCPC Hold
- FBIO Strong Buy
- Analyst Count
- TCPC 5
- FBIO 3
- Target Price
- TCPC $8.38
- FBIO $21.00
- AVG Volume (30 Days)
- TCPC 772.3K
- FBIO 247.1K
- Earning Date
- TCPC 05-08-2025
- FBIO 05-14-2025
- Dividend Yield
- TCPC 21.14%
- FBIO N/A
- EPS Growth
- TCPC N/A
- FBIO N/A
- EPS
- TCPC N/A
- FBIO N/A
- Revenue
- TCPC $259,437,390.00
- FBIO $57,675,000.00
- Revenue This Year
- TCPC N/A
- FBIO $63.20
- Revenue Next Year
- TCPC N/A
- FBIO $66.70
- P/E Ratio
- TCPC N/A
- FBIO N/A
- Revenue Growth
- TCPC 23.94
- FBIO N/A
- 52 Week Low
- TCPC $6.27
- FBIO $1.33
- 52 Week High
- TCPC $11.52
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- TCPC 36.21
- FBIO 46.68
- Support Level
- TCPC $6.36
- FBIO $1.45
- Resistance Level
- TCPC $6.81
- FBIO $1.64
- Average True Range (ATR)
- TCPC 0.37
- FBIO 0.13
- MACD
- TCPC -0.03
- FBIO 0.00
- Stochastic Oscillator
- TCPC 28.26
- FBIO 64.52
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.